Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Summary, in English

Protein kinase C (PKC) belongs to a family of ten serine/threonine protein kinases encoded by nine genes. This family of proteins plays critical roles in signal transduction which results in cell proliferation, survival, differentiation and apoptosis. Due to differential subcellular localization and tissue distribution, each member displays distinct signaling characteristics. In this review, we have summarized the roles of PKC family members in chronic lymphocytic leukemia (CLL). CLL is a heterogeneous hematological disorder with survival ranging from months to decades. PKC isoforms are differentially expressed in CLL and play critical roles in CLL pathogenesis. Thus, isoform-specific PKC inhibitors may be an attractive option for CLL treatment.

• Author: Julhash U. Kazi; Nuzhat N Kabir; Lars Rönnstrand
• Department/s: Department of Translational Medicine; BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
• Publishing year: 2013
• Language: English
• Pages: 757-757
• Publication/Series: Medical Oncology
• Volume: 30
• Issue: 4
• Full text: - 4 MB; Download statistics
• Links: http://www.ncbi.nlm.nih.gov/pubmed/24174318?dopt=Abstract; http://dx.doi.org/10.1007/s12032-013-0757-7
• Document type: Journal article review
• Publisher: Humana Press
• Topic: Cancer and Oncology
• Status: Published
• ISBN/ISSN/Other: ISSN: 1559-131X